Arena initiates phase I trial of APD811 for hypertension

Friday, October 12, 2012 02:46 PM

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company focused on novel drugs for weight management, cardiovascular disease, inflammation and other disorders, has initiated dosing in a phase I multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

This randomized, double-blind and placebo-controlled dose titration trial is planned to enroll up to 30 healthy adult volunteers, and will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule. Arena previously evaluated single-ascending doses of APD811 in the initial phase I clinical trial.

"Treatment with prostacyclin receptor agonists is considered standard of care for advanced PAH, but approved drugs in this class require intravenous, subcutaneous or inhaled delivery methods," said William R. Shanahan, M.D., senior vice president and CMO, Arena. "APD811 has the potential to improve treatment for this life-threatening disorder by providing patients with an oral, once-daily option targeting the prostacyclin receptor. This drug candidate was discovered internally by our scientists as part of our effort to bring best-in-class treatments to patients."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs